Literature DB >> 18355683

Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins.

Nathan E Basken1, Carla J Mathias, Alexander E Lipka, Mark A Green.   

Abstract

INTRODUCTION: Interactions of three copper(II) bis(thiosemicarbazone) positron emission tomography radiopharmaceuticals with human serum albumin, and the serum albumins of four additional mammalian species, were evaluated.
METHODS: 64Cu-labeled diacetyl bis(N4-methylthiosemicarbazonato)copper(II) (Cu-ATSM), pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II) (Cu-PTSM) and ethylglyoxal bis(thiosemicarbazonato)copper(II) (Cu-ETS) were synthesized and their binding to human, canine, rat, baboon and porcine serum albumins quantified by ultrafiltration. Protein binding was also measured for each tracer in human, porcine, rat and mouse serum.
RESULTS: The interaction of these neutral, lipophilic copper chelates with serum albumin is highly compound- and species-dependent. Cu-PTSM and Cu-ATSM exhibit particularly high affinity for human serum albumin (HSA), while the albumin binding of Cu-ETS is relatively insensitive to species. At HSA concentrations of 40 mg/ml, "% free" (non-albumin-bound) levels of radiopharmaceutical were 4.0+/-0.1%, 5.3+/-0.2% and 38.6+/-0.8% for Cu-PTSM, Cu-ATSM and Cu-ETS, respectively.
CONCLUSIONS: Species-dependent variations in radiopharmaceutical binding to serum albumin may need to be considered when using animal models to predict the distribution and kinetics of these compounds in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355683      PMCID: PMC2388251          DOI: 10.1016/j.nucmedbio.2007.11.009

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  32 in total

1.  The characterization of two specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

2.  Porcine IgG. Isolation of two IgG-subclasses and anti-IgG class- and subclass-specific antibodies.

Authors:  B A Bokhout; J J van Asten-Noordijk; W Stok
Journal:  Mol Immunol       Date:  1986-06       Impact factor: 4.407

3.  Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).

Authors:  Jason S Lewis; Pilar Herrero; Terry L Sharp; John A Engelbach; Yasuhisa Fujibayashi; Richard Laforest; Attila Kovacs; Robert J Gropler; Michael J Welch
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

Review 4.  PET imaging of hypoxia.

Authors:  J S Lewis; M J Welch
Journal:  Q J Nucl Med       Date:  2001-06

5.  Comparative properties of the antineoplastic agent, 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) copper(II) and related chelates: linear free energy correlations.

Authors:  D A Winkelmann; Y Bermke; D H Petering
Journal:  Bioinorg Chem       Date:  1974-04

6.  Copper-62-pyruvaldehyde bis(N-methyl-thiosemicarbazone) PET imaging in the detection of coronary artery disease in humans.

Authors:  T R Wallhaus; J Lacy; R Stewart; J Bianco; M A Green; N Nayak; C K Stone
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

7.  Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion.

Authors:  Mark A Green; Carla J Mathias; Lynn R Willis; Rajash K Handa; Jeffrey L Lacy; Michael A Miller; Gary D Hutchins
Journal:  Nucl Med Biol       Date:  2007-04       Impact factor: 2.408

8.  Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells.

Authors:  A Obata; E Yoshimi; A Waki; J S Lewis; N Oyama; M J Welch; H Saji; Y Yonekura; Y Fujibayashi
Journal:  Ann Nucl Med       Date:  2001-12       Impact factor: 2.668

Review 9.  Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance.

Authors:  Carlo Bertucci; Enrico Domenici
Journal:  Curr Med Chem       Date:  2002-08       Impact factor: 4.530

10.  Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells.

Authors:  D T Minkel; L A Saryan; D H Petering
Journal:  Cancer Res       Date:  1978-01       Impact factor: 12.701

View more
  9 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

Review 2.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

Review 3.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

4.  Elucidation of the human serum albumin (HSA) binding site for the Cu-PTSM and Cu-ATSM radiopharmaceuticals.

Authors:  Nathan E Basken; Carla J Mathias; Mark A Green
Journal:  J Pharm Sci       Date:  2009-06       Impact factor: 3.534

5.  Assessing Glomerular Filtration in Small Animals Using [68Ga]DTPA and [68Ga]EDTA with PET Imaging.

Authors:  Daniel Gündel; Ulrike Pohle; Erik Prell; Andreas Odparlik; Oliver Thews
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

6.  Cu(II) bis(thiosemicarbazone) radiopharmaceutical binding to serum albumin: further definition of species dependence and associated substituent effects.

Authors:  Nathan E Basken; Mark A Green
Journal:  Nucl Med Biol       Date:  2009-05-08       Impact factor: 2.408

7.  Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.

Authors:  Christin Neuber; Birgit Belter; Sebastian Meister; Frank Hofheinz; Ralf Bergmann; Hans-Jürgen Pietzsch; Jens Pietzsch
Journal:  Molecules       Date:  2018-02-17       Impact factor: 4.411

Review 8.  Development of copper based drugs, radiopharmaceuticals and medical materials.

Authors:  Paweł Szymański; Tomasz Frączek; Magdalena Markowicz; Elżbieta Mikiciuk-Olasik
Journal:  Biometals       Date:  2012-08-23       Impact factor: 2.949

Review 9.  The copper radioisotopes: a systematic review with special interest to 64Cu.

Authors:  Artor Niccoli Asabella; Giuseppe Lucio Cascini; Corinna Altini; Domenico Paparella; Antonio Notaristefano; Giuseppe Rubini
Journal:  Biomed Res Int       Date:  2014-05-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.